BioCentury
ARTICLE | Company News

Bristol-Myers, Duke University deal

March 5, 2012 8:00 AM UTC

Bristol-Myers and the university's Duke Translational Medicine Institute will co-develop and co-implement the protocol for a Phase II trial of the pharma's BMS-986202 (formerly AM152) for idiopathic pulmonary fibrosis (IPF). The trial is slated to begin late this year. The partners also will conduct biomarker validation studies. BMS gained rights to the orally sophosphatidic acid receptor 1 ( LPA1) antagonist through its acquisition of Amira Pharmaceuticals Inc. last year (see BioCentury, Sept. 12, 2011). ...